http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#Head http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#assertion http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#provenance http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#pubinfo http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#assertion http://purl.obolibrary.org/obo/DOID_526 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_526 http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01232 http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association http://www.w3.org/2000/01/rdf-schema#label invirase in combination with ritonavir and other antiretroviral agents is indicated for the treatment of hiv infection the twice daily administration of invirase in combination with ritonavir is supported by safety data from the maxcmin 1 study see table 6 table 1 in a randomized double blind clinical study nv14256 in zidovudine experienced hiv infected patients invirase in combination with zalcitabine was shown to be superior to either invirase or zalcitabine monotherapy in decreasing the cumulative incidence of clinical disease progression to aids defining events or death furthermore in a randomized study actg229 nv14255 patients with advanced hiv infection with history of prolonged zidovudine treatment and who were given invirase 6 mg three times daily zidovudine zalcitabine experienced greater increases in cd4 cell counts as compared to those who received invirase zidovudine or zalcitabine zidovudine it should be noted that hiv treatment regimens that were used in these initial clinical studies of invirase are no longer considered standard of care saquinavir gel capsule 1 mg twice daily coadministered with ritonavir 1 mg twice daily was studied in a heterogeneous population of 148 hiv infected patients maxcmin 1 study at baseline 42 were treatment naive and 1 6 were treatment experienced of which 52 had an hiv rna level 4 copies ml at baseline results showed that 91 148 61 subjects achieved and or sustained an hiv rna level 4 copies ml at the completion of 48 weeks http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01232 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#provenance http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#pubinfo http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#sig http://purl.org/nanopub/x/hasSignature N/rMIAQH8jquMe7BsSS7HUOqhWrZACQNBuwj5UgBEXb0lF2Sc+Ps8ud2PeLm3u/7MljUWgY/MoFIefhDnLSSVCWnD4OKg4r7bH3e6K3nghW1on+Tx/Si93TONhSB6khz708vG525cVw04yHPwR4acwVzdSXE4nSqras2HshGnKY= http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M http://purl.org/dc/terms/created 2021-06-14T08:21:22.795+02:00 http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs